hs-cTnT-gen6在疑诊心梗中的诊断效能与界值
这项基于APACE研究的二次分析纳入3346例急诊疑诊心梗患者,评估新一代hs-cTnT-gen6检测的诊断性能。结果显示,hs-cTnT-gen6与gen5诊断准确性相当(AUC 0.927 vs 0.931),但肌钙蛋白高于参考上限的患者比例更低(35.9% vs 43.5%)。研究推导并验证了适用于ESC 0/1小时和0/2小时流程的检测特异性界值。
要点
- hs-cTnT-gen6心肌损伤检出比例低于gen5(35.9% vs 43.5%),可减少非必要诊疗。
- 就诊时<6 ng/L无论胸痛时间均可安全排除NSTEMI(敏感度100%)。
- 0/1小时流程:<8或<18 ng/L且△<2 ng/L排除56.3%,≥112 ng/L或△≥10 ng/L纳入20.0%。
核心结论
- hs-cTnT-gen6诊断准确性极佳(AUC 0.927),与hs-cTnT-gen5相当,但心肌损伤检出比例更低。
- 基于ESC 0/1小时和0/2小时流程的检测特异性界值具有很高的敏感度和特异度。
研究设计与样本
- 研究设计:国际前瞻性诊断研究APACE的二次分析,采用中心化终点裁定。
- 对象:急诊就诊的疑诊心梗患者,共纳入3346例,其中616例(18.4%)最终诊断为心梗。
- 方法:在相同时间点检测hs-cTnT-gen6和hs-cTnT-gen5,比较两者分析与诊断性能,推导并内外部验证流程界值。
主要发现
- hs-cTnT-gen6就诊时AUC为0.927(95%CI: 0.918-0.937),gen5为0.931(95%CI: 0.921-0.94)。
- hs-cTnT-gen6检测值高于参考上限的患者比例为35.9%,低于gen5的43.5%(P<0.001)。
- 就诊时<6 ng/L排除NSTEMI的比例为30.0%,敏感度100%(95%CI: 99.4%-100%),与胸痛发作时间无关。
- 0/1小时流程排除56.3%的患者,敏感度99.7%(95%CI: 98.3%-99.9%)。
关键数值与推荐
- 即刻排除:就诊时hs-cTnT-gen6 <6 ng/L可排除NSTEMI(无论胸痛发作时间)。
- 0/1小时排除:就诊时<8 ng/L(胸痛>3小时)或<18 ng/L且0/1小时△<2 ng/L。
- 0/1小时纳入:就诊时≥112 ng/L或0/1小时△≥10 ng/L,纳入20.0%,特异度93.4%(95%CI: 92.0%-94.6%)。
- 0/2小时排除:就诊时<8 ng/L(胸痛>3小时)或<18 ng/L且0/2小时△<4 ng/L,排除51.1%,敏感度99.7%(95%CI: 98.1%-99.9%)。
- 0/2小时纳入:就诊时≥112 ng/L或0/2小时△≥15 ng/L,纳入23.9%,特异度92.7%(95%CI: 90.8%-94.2%)。
临床怎么用
- 使用hs-cTnT-gen6检测时,应采用该检测特异性的ESC 0/1小时或0/2小时流程界值进行快速分诊。
- hs-cTnT-gen6可减少被归类为心肌损伤的患者,更精准聚焦高危人群。
- 外部验证队列结果一致,支持该界值在不同人群中的推广使用。
局限性
- 研究为前瞻性诊断研究的二次分析,非专门针对gen6设计的前瞻性验证。
- 未提供患者人口学特征、肾功能等基线信息对检测性能的影响分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The new high-sensitivity cardiac troponin (hs-cTn) T-generation (gen) 6 assay has higher analytical sensitivity than the current hs-cTnT-gen5 assay, but its clinical performance is unknown. OBJECTIVES: The authors aimed to assess the clinical performance and use-optimized cutoffs of the hs-cTnT-gen6 assay. METHODS: In this secondary analysis of an international, prospective, diagnostic study with central adjudication, patients presenting with suspected myocardial infarction to the emergency department were enrolled. hs-cTnT-gen6 and hs-cTnT -gen5 were measured at the same time points. The analytical and diagnostic performance of hs-cTnT-gen6 were compared to hs-cTnT-gen5, and assay-specific cutoffs for the European Society of Cardiology 0/1- and 0/2-hour algorithms were derived and internally and externally validated. RESULTS: Among 3,346 patients, myocardial infarction was the final diagnosis in 616 (18.4%). The proportion of patients with concentrations above the upper reference limit and therefore having myocardial injury was lower for hs-cTnT-gen6 (35.9%) than for hs-cTnT-gen5 (43.5%; P < 0.001). Diagnostic accuracy at emergency department presentation, expressed as area under the curve, was 0.927 (95% CI: 0.918-0.937) for hs-cTnT-gen6 and 0.931 (95% CI: 0.921-0.94) for hs-cTnT-gen5. A gen6 cutoff of <6 ng/L ruled out non-ST-segment elevated myocardial infarction in 30.0% of patients with 100% sensitivity (95% CI: 99.4%-100%) irrespective of chest pain onset. An hs-cTnT-gen6 cutoff of <8 ng/L at presentation (if chest pain onset was >3 hours) or <18 ng/L together with a 0/1-hour delta of <2 ng/L ruled out 56.3% with a sensitivity of 99.7% (95% CI: 98.3%-99.9%). An hs-cTnT-gen6 concentration ≥112 ng/L or a 0/1-hour delta ≥10 ng/L ruled-in 20.0% with a specificity of 93.4% (95% CI: 92.0%-94.6%). An hs-cTnT-gen6 cutoff <8 ng/L at presentation (if chest pain onset was >3 hours) or <18 ng/L together with a 0/2-hour delta of <4 ng/L ruled out 51.1% with a sensitivity of 99.7% (95% CI: 98.1%-99.9%). An hs-cTnT-gen6 concentration ≥112 ng/L or a 0/2-hour delta ≥15 ng/L ruled-in 23.9% with a specificity 92.7% (95% CI: 90.8%-94.2%). Findings were consistent in sensitivity analyses as well as in the external validation cohort. CONCLUSIONS: The novel hs-cTnT-gen6 assay demonstrated excellent and comparable diagnostic performance to the established hs-cTnT-gen5 assay with fewer patients identified as having myocardial injury. Use-optimized, assay-specific cutoffs for the European Society of Cardiology 0/1- and 0/2-hour algorithms provided very high sensitivity and high specificity. (Advantageous Predictors of Acute Coronary Syndromes Evaluation Study [APACE]; NCT00470587).
引用
- Koechlin, Lopez-Ayala, Thurston, et al. High-Sensitivity Cardiac Troponin T-gen6 Assay in Suspected Myocardial Infarction: Diagnostic Accuracy, Cutoffs, and Clinical Implications. J Am Coll Cardiol. 2026. PMID: 41879583. doi:10.1016/j.jacc.2025.12.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。